Baidu Inc vs Merck & Co., Inc. — how do they compare? Baidu Inc trades at $104.44 (market cap $36.18B), while Merck & Co., Inc. trades at $132.9 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 8.9× Baidu Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Baidu Inc pays none. Which is the better fit depends on your goals.
| BIDU | MRK | |
|---|---|---|
Market Cap | $36.18B | $321.77B |
Sector | Media | Health |
52-Week High | $162.52 | $131.84 |
52-Week Low | $86.76 | $77.60 |
Enterprise Value | $32.81B | $368.53B |
Dividend Yield | — | 2.61% |
Signals from Pluang's Aura AI — not financial advice
Baidu (BIDU) trades at $103.7, down 5.3% in the last session, reflecting bearish technical signals and recent earnings volatility. The stock shows weak profitability with a net margin of 1.02% and elevated P/E of 78.19, though it trades below book value. Recent news highlights autonomous vehicle testing in London and an upcoming Q2 2026 earnings report on August 18, 2026 (PRNewsWire, 2026-07-31).
Outlook is mixed: strong analyst buy consensus (75.47%) and a $169.80 price target suggest upside, but declining revenue, negative cash flows, and China market risks pose headwinds. AI initiatives offer growth potential, but investors face execution and macroeconomic uncertainties.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →